Dataset opportunity
Diabeloop — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Diabeloop, usable for Diagnostic AI and Computer Vision.
Score
68.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in medical imaging market = $1.75B in 2024, CAGR 30% (2024-2030)
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs.
medtechdive.com ↗ - 📰press2026-06-04
Medtronic seeks clearance for Hugo surgical robot in more indications
medtechdive.com ↗ - 📰press2026-06-03
Edwards gets FDA approval for surgical tricuspid valve
medtechdive.com ↗ - 📰press2026-06-03
MiniMed expands Abbott partnership to add dual glucose-ketone sensor
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Diabeloop possesses a Medical Imaging Dataset (Image modality) complemented by data_catalog, event_streams, iot_data, and medical_records. This rich, multimodal data is crucial for developing advanced Diagnostic AI solutions, enabling comprehensive analysis and pattern identification for improved disease detection and personalized treatment strategies.
The business value of such data is substantial, driving a rapidly growing market. Despite challenges like highly sensitive patient health data, regulatory hurdles, and the need for consent management and anonymization/aggregation, the rarity and comprehensiveness of this integrated dataset make it exceptionally valuable. High-quality medical imaging datasets are in strong demand for training robust AI models, enhancing diagnostic accuracy, and supporting precision medicine. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive patient health data (GDPR-sensitive); Regulatory hurdles for medical devices and health data; Data ownership by patients/users requires careful consent management; Requires anonymization/aggregation for broader use beyond individual treatment · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Diabeloop holds a compelling dataset featuring medical records explicitly categorized with an Image modality, complemented by extensive real-time physiological data and comprehensive patient history. This unique combination is highly valuable for Diagnostic AI development, particularly for medical-AI and diagnostic-imaging companies aiming to advance precision healthcare solutions. With the global AI in medical imaging market projected to grow at a 30% CAGR, this dataset offers a timely and robust foundation for training sophisticated AI models, enabling deeper insights into patient conditions and treatment efficacy.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
The global AI in diagnostics market, heavily reliant on medical imaging datasets, is projected to grow from USD 7.03 billion in 2025 to USD 209.63 billion by 2034, exhibiting a robust CAGR of 46.06%.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility32
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Diabeloop is a French MedTech SME that develops and commercializes automated insulin delivery systems for Type 1 diabetes, generating valuable physiological data as a by-product of its operational business, and does not primarily sell data or AI intelligence as a core product. Issues: The initial description of the opportunity as a 'Medical Imaging Dataset' is inaccurate; Diabeloop's data relates to physiological measurements (glucose, insuli
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This evidence confirms the availability of real-time glucose measurements as Time Series data, crucial for developing predictive AI models in diabetes management and personalized treatment.
Medical records / imaging
This entry indicates patient physiology and history data, explicitly categorized with an Image modality, offering critical context for Diagnostic AI applications and advanced medical insights.
Event streams
This evidence details Automated Insulin Delivery (AID) system data, including continuous glucose monitoring as Time Series, invaluable for AI models focused on optimizing treatment efficacy.
Data catalog / marketplace
This entry describes a rich multimodal dataset comprising physiological data and a comprehensive history of events, offering a holistic view essential for training sophisticated AI models.
Coverage
Scanned sources
Deliverable
Premium dataset report
Diabeloop Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = $1.75B in 2024, CAGR 30% (2024-2030). Investment score 68.4/100 (confidence 0.56). Recommended action: Data Sharing Agreement.